Profile data is unavailable for this security.
About the company
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).
- Revenue in USD (TTM)21.73m
- Net income in USD-91.17m
- Incorporated1992
- Employees323.00
- Locationbluebird bio Inc455 Grand Union BoulevardSOMERVILLE 02145United StatesUSA
- Phone+1 (339) 499-9300
- Fax+1 (302) 636-5454
- Websitehttps://www.bluebirdbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Atossa Therapeutics Inc | 0.00 | -30.09m | 177.93m | 10.00 | -- | 1.95 | -- | -- | -0.2386 | -0.2386 | 0.00 | 0.7264 | 0.00 | -- | -- | 0.00 | -27.39 | -29.97 | -28.80 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
Alimera Sciences Inc | 80.75m | -21.39m | 180.10m | 159.00 | -- | 3.90 | -- | 2.23 | -2.16 | -2.16 | 3.17 | 0.8819 | 0.8235 | 6.22 | 2.98 | 507,886.80 | -20.53 | -19.08 | -29.94 | -27.37 | 86.58 | 86.80 | -24.93 | -19.55 | 2.31 | -0.1919 | 0.5835 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
bluebird bio Inc | 21.73m | -91.17m | 181.41m | 323.00 | -- | 0.4583 | -- | 8.35 | -0.7446 | -0.7446 | 0.2139 | 2.08 | 0.0383 | -- | -- | 67,263.16 | -16.08 | -33.02 | -21.50 | -37.14 | -10.08 | 19.44 | -419.62 | -4,044.31 | 1.42 | -- | 0.00 | -- | -1.77 | -36.71 | 52.62 | -- | -26.66 | -- |
Gossamer Bio Inc | 0.00 | -179.82m | 181.82m | 135.00 | -- | 2.89 | -- | -- | -1.38 | -1.38 | 0.00 | 0.2785 | 0.00 | -- | -- | 0.00 | -61.54 | -57.43 | -74.38 | -64.38 | -- | -- | -- | -- | -- | -15.09 | 0.769 | -- | -- | -- | 21.61 | -- | -- | -- |
Kodiak Sciences Inc | 0.00 | -260.49m | 182.20m | 111.00 | -- | 0.6856 | -- | -- | -4.97 | -4.97 | 0.00 | 5.06 | 0.00 | -- | -- | 0.00 | -45.46 | -31.73 | -49.53 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
Rigel Pharmaceuticals Inc | 116.88m | -25.09m | 184.17m | 147.00 | -- | -- | -- | 1.58 | -0.1444 | -0.1444 | 0.6717 | -0.1638 | 0.9295 | 0.9713 | 3.30 | 795,115.60 | -19.95 | -28.82 | -37.72 | -47.26 | 93.92 | 97.88 | -21.47 | -35.76 | 1.76 | -4.45 | 1.93 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
Generation Bio Co | 5.90m | -126.61m | 184.81m | 174.00 | -- | 0.9061 | -- | 31.30 | -1.97 | -1.97 | 0.0916 | 3.07 | 0.0157 | -- | 2.71 | 33,931.04 | -33.72 | -36.96 | -36.60 | -39.21 | -- | -- | -2,144.51 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
Outlook Therapeutics Inc | 0.00 | -51.50m | 184.85m | 24.00 | -- | -- | -- | -- | -3.99 | -3.99 | 0.00 | -1.87 | 0.00 | -- | -- | 0.00 | -122.07 | -214.69 | -441.62 | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -- | 3.00 | -- | -- | -- | 10.70 | -- | -- | -- |
Trevi Therapeutics Inc | 0.00 | -29.07m | 185.16m | 25.00 | -- | 2.22 | -- | -- | -0.2934 | -0.2934 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -27.37 | -47.39 | -30.09 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
Alpha Tau Medical Ltd | 0.00 | -29.16m | 185.32m | 121.00 | -- | 2.19 | -- | -- | -0.4203 | -0.4203 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -25.63 | -- | -26.99 | -- | -- | -- | -- | -- | -- | -- | 0.0623 | -- | -- | -- | 13.64 | -- | -- | -- |
Omeros Corp | 0.00 | -174.92m | 186.00m | 198.00 | -- | -- | -- | -- | -2.79 | -1.88 | 0.00 | -0.4087 | 0.00 | -- | -- | 0.00 | -36.09 | -55.51 | -44.88 | -70.10 | -- | -- | -- | -- | -- | -5.33 | 1.08 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
Prelude Therapeutics Inc | 0.00 | -121.83m | 188.93m | 128.00 | -- | 0.7968 | -- | -- | -2.05 | -2.05 | 0.00 | 4.32 | 0.00 | -- | -- | 0.00 | -48.91 | -47.21 | -53.60 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
Acumen Pharmaceuticals Inc | 0.00 | -52.37m | 189.85m | 51.00 | -- | 0.6855 | -- | -- | -1.08 | -1.08 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -20.67 | -- | -21.56 | -- | -- | -- | -- | -- | -- | -- | 0.103 | -- | -- | -- | -22.20 | -- | -- | -- |
Lifecore Biomedical Inc | 103.27m | -64.24m | 192.90m | 459.00 | -- | -- | -- | 1.87 | -2.12 | -3.29 | 3.43 | 1.16 | 0.391 | 1.96 | 3.07 | 224,986.90 | -24.32 | -5.67 | -41.13 | -8.07 | 27.10 | 21.91 | -62.20 | -11.90 | 1.35 | -1.05 | 0.7495 | -- | -7.19 | -27.74 | -315.07 | -- | -8.55 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Dec 2023 | 8.67m | 4.50% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 8.13m | 4.22% |
Granahan Investment Management, LLCas of 31 Dec 2023 | 8.08m | 4.19% |
Alyeska Investment Group LPas of 31 Dec 2023 | 6.91m | 3.59% |
Pictet Asset Management SAas of 31 Dec 2023 | 5.69m | 2.95% |
Norges Bank Investment Managementas of 31 Dec 2023 | 4.00m | 2.07% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.43m | 1.78% |
Millennium Management LLCas of 31 Dec 2023 | 3.41m | 1.77% |
Palo Alto Investors LPas of 31 Dec 2023 | 3.33m | 1.73% |
Ghisallo Capital Management LLCas of 31 Dec 2023 | 3.15m | 1.63% |